跳至主要内容
临床试验/ACTRN12615000471583
ACTRN12615000471583已完成不适用

A randomised crossover trial investigating the effect of the Fisher & Paykel Healthcare AIRVO high flow nasal therapy on PaCO2 in patients with stable COPD.

Medical Research Institute of New Zealand0 个研究点目标入组 48 人开始时间: 2015年5月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 o limit(—)
性别
All

入选标准

  • 1. A doctor’s diagnosis of COPD
  • 2. Age greater than or equal to 40 years

排除标准

  • 1.Smoking pack year history <10 years
  • 2.FEV1/FVC >70%
  • 3.Long term oxygen therapy
  • 4.COPD not deemed to be ‘stable’:
  • a.Current exacerbation requiring acute treatment with short course antibiotic/oral steroid or oxygen therapy.
  • b.Hospital admission for an acute exacerbation of COPD in the last 6 weeks.
  • 5.Nasal conditions such as deviated septum, chronic rhinitis, current cold/flu which, in the evaluation by the investigator, could impair nasal breathing.
  • 6.Any other condition, which at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or study results.

研究者

相似试验